Funding Daily Summary
Funding Daily Summary: What Happened on October 15, 2026
OMass raises $310 million to advance its drug pipeline
OMass plans to fund midstage work on an adrenal hormone drug and early clinical development in autoimmune disease. Iambic raised $150 million in an IPO.
Today in brief
OMass Therapeutics raised $310 million in a Series C, the second-largest private biotech round in Europe this year.1 Iambic raised $150 million in an IPO.2
OMass raises $310 million for pipeline development
OMass Therapeutics raised $310 million in an oversubscribed Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings, with new and existing investors participating.1 The round brings OMass’s total funding to about $475 million, behind only Isomorphic’s $2.1 billion Series B in May among Europe’s private biotech financings this year.1
OMass plans to use most of the proceeds to advance OMS1620 through Phase 2 for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.1 The company aims to block adrenocorticotropic hormone (ACTH) activity at the adrenal gland, lowering androgen production while allowing patients to take lower glucocorticoid doses.1 OMass said the financing will also support early clinical development of an SLC15A4 inhibitor for lupus and other autoimmune diseases.1
Iambic raises $150 million in IPO
Iambic raised $150 million in an initial public offering, taking the AI drug discovery company public.2 In regulatory filings, Iambic said its approach could substantially change established drug discovery methods.2